Page 279 - Williams Hematology ( PDFDrive )

254 Part IV: Molecular and Cellular Hematology Chapter 17: Signal Transduction Pathways 255

REFERENCES 36. Shi Y, Massague J: Mechanisms of TGF-beta signaling from cell membrane to the
nucleus. Cell 113:685, 2003.
1. D’Andrea AD, Lodish HF, Wong GG: Expression cloning of the murine erythropoietin 37. Feng XH, Derynck R: Specificity and versatility in tgf-beta signaling through Smads.
receptor. Cell 57:277, 1989. Annu Rev Cell Dev Biol 21:659, 2005.
2. Watowich SS, Hilton DJ, Lodish HF: Activation and inhibition of erythropoietin recep- 38. Chen S, Lin F, Xu M, et al: Phe(303) in TMVI of the alpha(1B)-adrenergic receptor is
tor function: Role of receptor dimerization. Mol Cell Biol 14:3535, 1994. a key residue coupling TM helical movements to G-protein activation. Biochemistry
3. Livnah O, Stura EA, Middleton SA, et al: Crystallographic evidence for preformed 41:588, 2002.
dimers of erythropoietin receptor before ligand activation. Science 283:987, 1999. 39. Bessis AS, Rondard P, Gaven F, et al: Closure of the Venus flytrap module of mGlu8
4. Broudy VC, Lin N, Egrie J, et al: Identification of the receptor for erythropoietin on receptor and the activation process: Insights from mutations converting antagonists
human and murine erythroleukemia cells and modulation by phorbol ester and into agonists. Proc Natl Acad Sci U S A 99:11097, 2002.
dimethyl sulfoxide. Proc Natl Acad Sci U S A 85:6513, 1988. 40. Coughlin S: Protease-activated receptors in hemostasis, thrombosis and vascular biol-
5. Kanakura Y, Druker B, Cannistra SA, et al: Signal transduction of the human ogy. J Thromb Haemost 3:1800, 2005.
granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves 41. Slupsky JR, Quitterer U, Weber CK, et al: Binding of Gbetagamma subunits to cRaf1
tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood 76:706, downregulates G-protein-coupled receptor signalling. Curr Biol 9:971, 1999.
1990. 42. Levesque JP, Simmons PJ: Cytoskeleton and integrin-mediated adhesion signaling in
6. Spivak JL, Fisher J, Isaacs MA, et al: Protein kinases and phosphatases are involved in human CD34+ hemopoietic progenitor cells. Exp Hematol 27:579, 1999.
erythropoietin-mediated signal transduction. Exp Hematol 20:500, 1992. 43. Martin KH, Slack JK, Boerner SA, et al: Integrin connections map: To infinity and
7. Otani H, Erdos M, Leonard WJ: Tyrosine kinase(s) regulate apoptosis and bcl-2 expres- beyond. Science 296:1652, 2002.
sion in a growth factor-dependent cell line. J Biol Chem 268:22733, 1993. 44. Rose DM, Alon R, Ginsberg MH: Integrin modulation and signaling in leukocyte adhe-
8. Witthuhn BA, Quelle FW, Silvennoinen O, et al: JAK2 associates with the erythropoi- sion and migration. Immunol Rev 218:126, 2007.
etin receptor and is tyrosine phosphorylated and activated following stimulation with 45. Mitra SK, Schlaepfer DD: Integrin-regulated FAK-Src signaling in normal and cancer
erythropoietin. Cell 74:227, 1993. cells. Curr Opin Cell Biol 18:516, 2006.
9. Syed RS, Reid SW, Li C, et al: Efficiency of signalling through cytokine receptors 46. Sastry SK, Burridge K: Focal adhesions: A nexus for intracellular signaling and
depends critically on receptor orientation. Nature 395:511, 1998. cytoskeletal dynamics. Exp Cell Res 261:25, 2000.
10. Cheetham JC, Smith DM, Aoki KH, et al: NMR structure of human erythropoietin and 47. Schwartz MA, Ginsberg MH: Networks and crosstalk: Integrin signalling spreads. Nat
a comparison with its receptor bound conformation. Nat Struct Biol 5:861, 1998. Cell Biol 4:E65, 2002.
11. Wrighton NC, Farrell FX, Chang R, et al: Small peptides as potent mimetics of the 48. Schaller MD: Paxillin: A focal adhesion-associated adaptor protein. Oncogene 20:6459,
protein hormone erythropoietin. Science 273:458, 1996. 2001.
12. Li JP, D’Andrea AD, Lodish HF, et al: Activation of cell growth by binding of Friend 49. Aranda A, Pascual A: Nuclear hormone receptors and gene expression. Physiol Rev
spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature 81:1269, 2001.
343:762, 1990. 50. Mehta K: Retinoids as regulators of gene transcription. J Biol Regul Homeost Agents
13. Livnah O, Johnson DL, Stura EA, et al: An antagonist peptide-EPO receptor complex 17:1, 2003.
suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol 5:993, 51. Ahuja HS, Szanto A, Nagy L, et al: The retinoid X receptor and its ligands: Versatile reg-
1998. ulators of metabolic function, cell differentiation and cell death. J Biol Regul Homeost
14. Taga T, Kishimoto T: Gp130 and the interleukin-6 family of cytokines. Annu Rev Immu- Agents 17:29, 2003.
nol 15:797, 1997. 52. Carlberg C: Current understanding of the function of the nuclear vitamin D receptor in
15. Cornelissen C, Juliane Lüscher-Firzlaff J, Malte Baron J, Lüscher B. Signaling by IL-31 response to its natural and synthetic ligands. Recent Results Cancer Res 164:29, 2003.
and functional consequences. Eur J Cell Biol 91:552, 2012. 53. Collins SJ: Retinoic acid receptors, hematopoiesis and leukemogenesis. Curr Opin
16. Jones SA, Rose-John S: The role of soluble receptors in cytokine biology: The agonistic Hematol 15:346, 2008.
properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta 1592:251, 2002. 54. Ihle JN, Kerr IM: Jaks and Stats in signaling by the cytokine receptor superfamily.
17. Stahl N, Boulton TG, Farruggella T, et al: Association and activation of Jak-Tyk kinases Trends Genet 11:69, 1995.
by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263:92, 1994. 55. Parganas E, Wang D, Stravopodis D, et al: Jak2 is essential for signaling through a vari-
18. Pflanz S, Kurth I, Grotzinger J, et al: Two different epitopes of the signal transducer ety of cytokine receptors. Cell 93:385, 1998.
gp130 sequentially cooperate on IL-6-induced receptor activation. J Immunol 165:7042, 56. Saharinen P, Vihinen M, Silvennoinen O: Autoinhibition of Jak2 tyrosine kinase is
2000. dependent on specific regions in its pseudokinase domain. Mol Biol Cell 14:1448, 2003.
19. Baiocchi M, Marcucci I, Rose-John S, et al: An IL-6/IL-6 soluble receptor (IL-6R) 57. Silvennoinen O, Ungureanu D, Niranjan Y, et al: New insights into the structure and
hybrid protein (H-IL-6) induces EPO-independent erythroid differentiation in human function of the pseudokinase domain in JAK2. Biochem Soc Trans 41:1002, 2013.
CD34(+) cells. Cytokine 12:1395, 2000. 58. James C, Ugo V, LeCouedic JP, et al: A unique clonal JAK2 mutation leading to consti-
20. Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational tutive signaling causes polycythaemia vera. Nature 434:1144, 2005.
drug design. Curr Pharm Des 14:1217, 2008. 59. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2
21. Waldmann TA: T-cell receptors for cytokines: Targets for immunotherapy of leukemia/ in human myeloproliferative disorders. Lancet 365:1054, 2005.
lymphoma. Ann Oncol 11(Suppl 1):101, 2000. 60. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in
22. Henkels KM, Frondorf K, Gonzalez-Mejia ME, et al. IL-8-induced neutrophil chemo- myeloproliferative disorders. N Engl J Med 352:1779, 2005.
taxis is mediated by Janus Kinase 3 (Jak3). FEBS Lett 585:159, 2011. 61. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2
23. Leonard WJ: The molecular basis of X-linked severe combined immunodeficiency: in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelo-
Defective cytokine receptor signaling. Annu Rev Med 47:229, 1996. fibrosis. Cancer Cell 7:387, 2005.
24. Uribe L, Weinberg KI: X-linked SCID and other defects of cytokine pathways. Semin 62. Kaushansky K: On the molecular origins of the chronic myeloproliferative disorders: It
Hematol 35:299, 1998. all makes sense. Blood 105:4187, 2005.
25. von Freeden-Jeffry U, Vieira P, Lucian LA, et al: Lymphopenia in interleukin (IL)-7 63. Jung AS, Kaushansky A, Macbeath G, Kaushansky K: Tensin 2 is a novel mediator in
gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 181:1519, thrombopoietin (TPO)-induced cellular proliferation by promoting Akt signaling. Cell
1995. Cycle 10:1838, 2011.
26. Appasamy PM: Biological and clinical implications of interleukin-7 and lymphopoiesis. 64. Rameh LE, Cantley LC: The role of phosphoinositide 3-kinase lipid products in cell
Cytokines Cell Mol Ther 5:25, 1999. function. J Biol Chem 274:8347, 1999.
27. Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor super- 65. Vanhaesebroeck B, Alessi DR: The PI3K-PDK1 connection: More than just a road to
family. Nat Rev Cancer 2:420, 2002. PKB. Biochem J 346 Pt 3:561, 2000.
28. Aggarwal BB: Signalling pathways of the TNF superfamily: A double-edged sword. Nat 66. Chang F, Lee JT, Navolanic PM, et al: Involvement of PI3K/Akt pathway in cell cycle
Rev Immunol 3:745, 2003. progression, apoptosis, and neoplastic transformation: A target for cancer chemother-
29. Wang S, El-Deiry WS: TRAIL and apoptosis induction by TNF-family death receptors. apy. Leukemia 17:590, 2003.
Oncogene 22:8628, 2003. 67. Datta SR, Brunet A, Greenberg ME: Cellular survival: A play in three Akts. Genes Dev
30. Cabal-Hierro L, Lazo PS: Signal transduction by tumor necrosis factor receptors. Cell 13:2905, 1999.
Signal 24:1297, 2012. 68. Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol 3:221,
31. Sherr CJ: The role of the CSF-1 receptor gene (C-fms) in cell transformation. Leukemia 2002.
2:132S, 1988. 69. Tothova Z, Gilliland DG: FoxO transcription factors and stem cell homeostasis: Insights
32. Lyman SD, Jacobsen SE: c-Kit ligand and Flt3 ligand: Stem/progenitor cell factors with from the hematopoietic system. Cell Stem Cell 1:140, 2007.
overlapping yet distinct activities. Blood 91:1101, 1998. 70. Kawauchi K, Ogasawara T, Yasuyama M, et al: Involvement of Akt kinase in the action
33. Broudy VC: Stem cell factor and hematopoiesis. Blood 90:1345, 1997. of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis 31:11, 2003.
34. Linnekin D: Early signaling pathways activated by c-Kit in hematopoietic cells. Int J 71. Inman GJ, Nicolas FJ, Hill CS: Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits
Biochem Cell Biol 31:1053, 1999. sensing of TGF-beta receptor activity. Mol Cell 10:283, 2002.
35. Pandit J, Bohm A, Jancarik J, et al: Three-dimensional structure of dimeric human 72. Pawson T, Scott JD: Signaling through scaffold, anchoring, and adaptor proteins. Sci-
recombinant macrophage colony-stimulating factor. Science 258:1358, 1992. ence 278:2075, 1997.

Kaushansky_chapter 17_p0247-0256.indd 254 9/17/15 5:45 PM